MARKET

ADIL

ADIL

Adial
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.520
+0.130
+5.44%
Closed 16:00 03/02 EST
OPEN
2.410
PREV CLOSE
2.390
HIGH
2.570
LOW
2.352
VOLUME
410.96K
TURNOVER
--
52 WEEK HIGH
4.000
52 WEEK LOW
1.000
MARKET CAP
36.27M
P/E (TTM)
-3.0894
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial"), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it will host a Town Hall at 1 P.M., Eastern Time on Thursday, March 18, 20...
GlobeNewswire · 4d ago
Adial receives $1.43M in proceeds from warrants exercising
Adial Pharmaceuticals (ADIL) announced the exercise of 712,500 warrants from its June 2020 financing for net proceeds of $1.43M to the company.Press Release
Seekingalpha · 4d ago
Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants
CHARLOTTESVILLE, Va., Feb 26, 2021 (GLOBE NEWSWIRE via COMTEX) -- CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc....
GlobeNewswire · 4d ago
DJ Adial Pharmaceuticals Shares Drop 10% After Update on AD04 Trial
Dow Jones · 5d ago
Adial achieves 50% enrollment in late-stage ONWARD AD04 trial
Adial Pharmaceuticals ([[ADIL]] +4.2%) announces that it has reached 50% enrollment in the company’s landmark ONWARD pivotal Phase 3 clinical trial testing AD04 as a therapeutic agent for the treatment of Alcohol
Seekingalpha · 5d ago
BRIEF-Adial Pharmaceuticals Achieves 50% Enrollment In Onwar Phase 3 Trial
reuters.com · 5d ago
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD Phase 3 Trial
Adial Pharmaceuticals, Inc. (NASDAQ:ADIL, ADILW)), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment in the
Benzinga · 5d ago
BRIEF-Adial To File Fast Track Application For Ad04 With The FDA
reuters.com · 02/23 19:17
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ADIL. Analyze the recent business situations of Adial through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ADIL stock price target is 5.00 with a high estimate of 5.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 21
Institutional Holdings: 741.77K
% Owned: 5.15%
Shares Outstanding: 14.39M
TypeInstitutionsShares
Increased
3
15.80K
New
5
26.74K
Decreased
2
1.19K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.24%
Pharmaceuticals & Medical Research
-0.94%
Key Executives
President/Chief Executive Officer/Director
William Stilley
Vice Chairman/Lead Director/Independent Director
Kevin Schuyler
Chief Financial Officer/Chief Operating Officer/Treasurer/Secretary
Joseph Truluck
Other
Bankole Johnson
Independent Director
J. Kermit Anderson
Independent Director
Robertson Gilliland
Independent Director
Tony Goodman
Independent Director
James Newman
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About ADIL
Adial Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the development of medications for the treatment of addictions and related disorders. Its lead investigational drug product is AD04. AD04 is being developed for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist. AD04 is being designed to be used for the treatment of other addictive disorders, such as opioid use disorder, obesity, smoking, and other drug addictions.

Webull offers kinds of Adial Pharmaceuticals Inc stock information, including NASDAQ:ADIL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADIL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADIL stock methods without spending real money on the virtual paper trading platform.